Sign up to save your podcasts
Or
Share Pharmaceutical Executive
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Pharmaceutical Executive
Pharmaceutical Executive episodes
- Pharmaceutical Executive Daily: Novo Partners with AnthropicNovo teams up with Anthropic on AI-driven drug discovery, Sling Therapeutics and Circle Pharma close major financing rounds, and IQVIA's Phil Ford makes the case for reimagining medical content as a loop rather than a pipeline.3 min
- Pharmaceutical Executive Daily: Sanofi & Cheplapharm Form Strategic PartnershipGSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership with Cheplapharm, Stewart Gandolf discusses why pharma marketing now has to write for both people and AI, and Dr. Elena Christofides explains why cortisol dysregulation may be the hidden reason some diabetes patients fail to respond to incretin therapies.4 min
- Pharmaceutical Executive Daily: Novo Nordisk Enters RebrandCellectis pivots from CAR-T to in vivo gene editing, Novo Nordisk rebrands as "Novo" to sharpen its competitive edge in obesity and diabetes care, and Wendy Short Bartie of Bristol Myers Squibb makes the case for reputation as a strategic currency.4 min
- Pharmaceutical Executive Daily: Novartis Shareholders Raise Concerns over M&A StrategyNovartis investors intensify pressure on the company's M&A strategy after a string of trial failures, Michelle Carnahan argues health care needs an orchestration layer rather than more point solutions, and Nacho Quinones and Aisling O'Loughlin make the case for synthetic advisory boards in biopharma decision-making.3 min
- 3 min
- 340B Under Pressure: Inside Pharma's Push for Greater Clarity
In this episode of Pricing & Policy with Model N, Jesse Mendelsohn, senior vice president at Model N, joins host Mike Christel to examine the growing stakes surrounding the 340B Drug Pricing Program — and how claims data, rebate models and legal challenges are shaping manufacturers’ response. Mendelsohn explains drugmaker concerns about overlapping discounts, the gaps in claims visibility that make them difficult to identify and the push to verify dispensing before paying a 340B rebate (all three at the heart of industry revenue leakage issues). Throughout the conversation, Mendelsohn considers what it will take to bring greater accountability and predictability to the program while preserving its underlying purpose.
00:53 - The evolution of 340B
03:39 - Understanding program's growth and impact
07:27 - Manufacturer challenges/complexities in compliance
10:43 - 340B's twisting path: Rebate pilots and more
15:44 - Pharma as key stakeholder
18:25 - Claims collection hurdles
20:56 - Lilly and industry strategy shifts
23:19 - Assessing the litigation landscape
25:37 - 340B's role in pricing pie, GTN management
29:20 - Fueling future debate? The two drivers
34 min - Pharmaceutical Executive Daily: Moonwalk Biosciences' $70 Million Series BAptar Pharma and Aceso Therapeutics team up to advance an inhaled cystic fibrosis therapy, Moonwalk Biosciences raises a $70 million Series B for its fat-targeted obesity platform, and Sebastian Arana of MilliporeSigma talks through the real cost of manufacturing flexibility.3 min
- Pharmaceutical Executive Daily: FDA Approves ZanvastroIonis wins FDA approval for Zanvastro, the first disease-modifying treatment for Alexander disease, Pharmaceutical Executive’s weekly biotech roundup gathers analyst reaction to the week's biggest stories, and Nate Hill of Strive Pharmacy talks through the regulatory uncertainty around compounded peptides.3 min
- Pharmaceutical Executive Daily: Ultragenyx's Apazunersen Fails Phase III TrialUltragenyx shares plunge after apazunersen fails its Phase III trial in Angelman syndrome, Mark Cziraky of Carelon Research talks through the mechanics of analyzing linked real-world data sets, and Melanie Whittington joins The Ron Lanton Report to argue biopharma policy needs to stay tethered to patients, not abstractions.4 min
- The Ron Lanton Report: What Are We Doing This All For?Melanie Whittington, managing director and head of the Leerink Center for Pharmacoeconomics, joins Ron Lanton to argue that biopharmaceutical policy only makes sense when traced back to its purpose.39 min
About Pharmaceutical Executive
From the publisher's feed
The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest…
commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.
More shows like Pharmaceutical Executive
Planet Money
30,652 Listeners
Economist Podcasts
4,094 Listeners
Motley Fool Hidden Gems Investing
3,158 Listeners
WSJ Your Money Briefing
1,714 Listeners
WSJ What’s News
4,325 Listeners
Bloomberg Businessweek
421 Listeners
WSJ Tech News Briefing
1,642 Listeners
HBR IdeaCast
145 Listeners
Bold Names
1,424 Listeners
The Indicator from Planet Money
9,507 Listeners
The Readout Loud
336 Listeners
Thoughts on the Market
1,297 Listeners
The Journal.
6,066 Listeners
Bloomberg Daybreak: US Edition
87 Listeners
WSJ's Take On the Week
144 Listeners